Detalles de la búsqueda
1.
LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis.
Immunity
; 49(2): 342-352.e5, 2018 08 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30097293
2.
Long-chain polyunsaturated lipids associated with responsiveness to anti-PD-1 therapy are colocalized with immune infiltrates in the tumor microenvironment.
J Biol Chem
; 299(3): 102902, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642178
3.
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Breast Cancer Res
; 22(1): 134, 2020 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33267869
4.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Nature
; 515(7528): 568-71, 2014 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25428505
5.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med
; 374(26): 2542-52, 2016 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27093365
6.
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Breast Cancer Res
; 20(1): 71, 2018 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29996881
7.
PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
J Neurooncol
; 139(2): 281-291, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29730815
8.
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Cancer
; 123(17): 3291-3304, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28463396
9.
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
Mod Pathol
; 30(11): 1516-1526, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28752839
10.
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.
Hematol Oncol
; 40(2): 302-306, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34806797
11.
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
Pediatr Blood Cancer
; 64(11)2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28488345
12.
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Mod Pathol
; 28(12): 1535-44, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26403784
13.
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
J Transl Med
; 13: 319, 2015 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26419843
14.
Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
Mol Ther Oncol
; 32(2): 200807, 2024 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38745749
15.
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
JCO Precis Oncol
; 7: e2200317, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099733
16.
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35793874
17.
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
Mol Cancer Ther
; 21(3): 427-439, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965960
18.
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.
Front Oncol
; 11: 598001, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33912442
19.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Clin Cancer Res
; 27(4): 1048-1057, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33199490
20.
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
J Immunother Cancer
; 8(2)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33127658